Acura Stock Story

All Stories . Risk . 
Ellen Johnson .  Story
ACUR
 Stock
  

USD 0.10  0.05  100.00%   

By Ellen Johnson
Macroaxis Story
It seems Acura Pharma may not recover as fast as we have hopped for as its price went down 1.96% today. Acura Pharma Cmn current daily volatility is 12.04 percent, with a beta of -0.6 and an alpha of 0.56 over DOW. As some retail investors are moving away from the latest market volatility spike, we are going to sum up Acura Pharma Cmn based on how it reacts to economic swings. We will evaluate why we are still optimistic in anticipation of a recovery.
Published over a month ago
View all stories for Acura Pharma | View All Stories

Should you keep an eye on Acura Pharma (OTC:ACUR) management before July?

Acura Pharma Cmn currently holds roughly 89 K in cash with (396 K) of positive cash flow from operations.
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Acura Pharma has an asset utilization ratio of 13.27 percent. This connotes that the company is making $0.13 for each dollar of assets. An increasing asset utilization means that Acura Pharma Cmn is more efficient with each dollar of assets it utilizes for everyday operations.
Investing in Acura Pharma, just like investing in any other equity instrument, is characterized by a strong risk-return correlation. High risks mean high returns and low risk means lower expected returns. Risk management is the act of identifying and assessing the potential risk and developing strategies to minimize these risks and earn maximum possible profits while holding Acura Pharma along with other instruments in the same portfolio. Using conventional technical analysis and fundamental analysis to select individual securities into a portfolio complements risk management and adds value to overall investors' investing strategies.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Acura Pharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Acura Pharma in the context of predictive analytics.
Hype
Prediction
Details
Intrinsic
Valuation
Details
Naive
Forecast
Details
1 Analysts
Consensus
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Acura Pharma. Your research has to be compared to or analyzed against Acura Pharma's peers to derive any actionable benefits. When done correctly, Acura Pharma's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Acura Pharma Cmn.

Watch out for price decline

Please consider monitoring Acura Pharma on a daily basis if you are holding a position in it. Acura Pharma is trading at a penny-stock level, and the possibility of delisting is much higher compared to other equities. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as Acura Pharma stock to be traded above the $1 level to remain listed. If Acura Pharma stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.

How important is Acura Pharma's Liquidity

Acura Pharma financial leverage refers to using borrowed capital as a funding source to finance Acura Pharma Cmn ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Acura Pharma financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Acura Pharma's total debt and its cash.

How does Acura utilize its cash?

To perform a cash flow analysis of Acura Pharma, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Acura Pharma is receiving and how much cash it distributes out in a given period. The Acura Pharma cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Acura Pharma Net Cash Flow from Operations is relatively stable at the moment as compared to the past year. Acura Pharma reported last year Net Cash Flow from Operations of (647,100)

Acura Pharma Correlation with Peers

Investors in Acura can reduce exposure to individual asset risk by holding a diversified portfolio of assets in addition to a long position in Acura Pharma Cmn. Diversification will allow for the same portfolio return with reduced risk. The correlation table of Acura Pharma and its peers is a two-dimensional matrix that shows the correlation coefficient between pairs of securities Acura is related in some way. The cells in the table are color-coded to highlight significantly positive and negative relationships. Each cell shows the correlation between one pair of equities and can be used to run pair trading strategies or create efficient portfolios with your current brokerage.
Please check volatility of Acura for more details

Detailed Outlook On Acura Pharma

Acura Pharma appears to be abnormally volatile, given 3 months investment horizon. Acura Pharma Cmn secures Sharpe Ratio (or Efficiency) of 0.0776, which signifies that the company had 0.0776% of return per unit of risk over the last 3 months. Our standpoint towards foreseeing the volatility of a stock is to use all available market data together with stock-specific technical indicators that cannot be diversified away. By analyzing Acura Pharma Cmn technical indicators you can presently evaluate if the expected return of 0.93% is justified by implied risk. Please makes use of Acura Pharma's Risk Adjusted Performance of 0.0742, mean deviation of 6.4, and Downside Deviation of 14.47 to double-check if our risk estimates are consistent with your expectations.
BBI
BLI
BLU
MBIO
BBIO
BBI
0.59-0.18-0.250.75
BBI
BLI
0.59-0.41-0.480.84
BLI
BLU
-0.18-0.410.68-0.14
BLU
MBIO
-0.25-0.480.68-0.35
MBIO
BBIO
0.750.84-0.14-0.35
BBIO
BBI
BLI
BLU
MBIO
BBIO
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio

Another setback for Acura Pharma retail investors

The mean deviation is down to 6.4 as of today. Acura Pharma Cmn is showing large volatility of returns over the selected time horizon. We encourage all investors to investigate this asset further to make sure related market timing strategies are aligned with all the expectations about Acura Pharma implied risk. Acura Pharma Cmn is a potential penny stock. Although Acura Pharma may be in fact a good instrument to invest, many penny otc stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Acura Pharma Cmn. We encourage investors to look for the signals such us email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Acura instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of an artificial hype usually unable to maintain its increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.

The Bottom Line

While some firms within the drug manufacturers—specialty & generic industry are still a little expensive, even after the recent corrections, Acura Pharma may offer a potential longer-term growth to retail investors. With an impartial outlook on the current market volatility, it may be better to hold off any inventment activity and neither buy nor drop any shares of Acura Pharma at this time. The Acura Pharma Cmn risk-reward trade off is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Acura Pharma.

Editorial Staff

Ellen Johnson is a Member of Macroaxis Editorial Board. Ellen covers public companies in North America, focusing primarily on valuation and volatility. Six years of experience in predictive investment analytics and risk management. View Profile
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Acura Pharma Cmn. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2022 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY